Press Releases Akeso, Inc.

Equities

9926

KYG0146B1032

Biotechnology & Medical Research

Delayed Hong Kong S.E. Other stock markets 01:39:05 15/05/2026 pm IST			5-day change	1st Jan Change
120.20 ^HKD	-2.91%		-10.30%	+6.37%

15/05	Akeso Inc Announces Phase II Data of Ligufalimab Combination Therapy in Frontline Acute Myeloid Leukemia	CI
28/04	Biodlink International Company Limited Announces Board and Board Committee Changes, Effective from 29 April 2026	CI

Press Releases

15/05	Phase II Data from a Randomized Double-Blind Trial of Ligufalimab (Anti-CD47) Combination Therapy in Frontline AML Published at EHA 2026	PR
28/04	Ivonescimab Receives Major Recommendations Across Multiple Therapies in the 2026 CSCO NSCLC Guideline	PR
21/04	Cadonilimab Combination Demonstrates Promising Survival Benefit in Locally Advanced Pancreatic Cancer: Phase II COMPASSION-26 Data Presented at AACR 2026	PR
07/04	Akeso Presents Updated Data on Cadonilimab Combination Therapy in PD-(L)1 Inhibitor-Resistant Advanced NSCLC at ELCC 2026	PR
31/03	Ivonescimab Shows Quality of Life Benefits in Chemotherapy-Free First-Line NSCLC: Health-Related Quality of Life Data from the HARMONi-2 Study Presented at ELCC 2026	PR
27/03	Akeso Reports Full-Year 2025 Financial Results	PR
25/03	Akeso Advances 'IO 2.0 + ADC 2.0' Strategy with Phase II Initiation of Novel ADCs Combined with Ivonescimab and Cadonilimab	AQ
25/03	Akeso Advances "IO 2.0 + ADC 2.0" Strategy with Phase II Initiation of Novel ADCs Combined with Ivonescimab and Cadonilimab	PR
16/03	Akeso Announces Global First-in-Class Trispecific Antibody AK150 Enters Clinical Trials: A Triple-Target Approach to Overcome Immunotherapy Resistance	PR
05/03	Cadonilimab Achieves 100% 24-Month OS in Complete Responders in R/M Cervical Cancer Based on Long-Term Phase II Results	PR
04/03	Akeso and INOVIO Announce Clinical Collaboration to Advance Novel Combination Therapy for Glioblastoma (GBM)	PR
04/03	INOVIO and Akeso Announce Clinical Collaboration to Advance Novel Combination Therapy for Glioblastoma (GBM)	PR
11/02	Akeso's IL-4Rα/ST2 Bispecific Antibody Cleared for Seven Phase II Studies in China Spanning Respiratory and Autoimmune Indications	PR
06/02	Akeso Receives Fifth Breakthrough Therapy Designation from NMPA for Ivonescimab in First-Line Treatment of Advanced Biliary Tract Cancer	PR
29/01	Ivonescimab Included in FirstWord Pharma's "The Drugs That Will Shape 2026"	PR
19/01	Akeso Announces NMPA Acceptance of Second NDA for Gumokimab (IL-17A Inhibitor) in Active Ankylosing Spondylitis	PR
14/01	Head-to-Head Real-World Data: Cadonilimab Outperforms PD-1 Inhibitors in First-Line PD-L1-Low Gastric Cancer	PR
07/01	Ivonescimab's Updated Label Shows Positive Dual Results in PFS and OS from HARMONi-A Study	PR
12/12	Cadonilimab (PD-1/CTLA-4) Receives FDA Clearance for Global Phase III First-Line Gastric Cancer Trial Versus Nivolumab	PR
11/12	Updated Efficacy Data of Ivonescimab Combined with Chemotherapy as First-Line Treatment for TNBC Presented at ESMO IO 2025	PR
09/12	Phase II Data of Cadonilimab Regimen as Neoadjuvant Therapy for Resectable Gastric Cancer Presented at ESMO Asia 2025	PR
09/12	Significant Improvement in Quality of Life Reported in Updated HARMONi-6 Data for Ivonescimab at ESMO Asia	PR
07/12	All Approved Indications of Five Akeso's Innovative Drugs Included in China's Latest NRDL: Featuring Two First-in-Class Bispecifics with New First-Line Indications and Three Newly Negotiated Drugs	PR
17/11	Akeso's Bispecific Antibody Targeting Aβ and BBB-Expressed Receptor Approved for Alzheimer's Disease Clinical Trials in China	PR
10/11	Akeso Announces First Patient Dosed in Phase I Trial of Personalized mRNA Vaccine AK154 as Monotherapy or in Combination with Cadonilimab or Ivonescimab for Adjuvant Treatment of Pancreatic Cancer	PR